EP4055176A4 - Vaccins anti-gucy2c et vaccination - Google Patents

Vaccins anti-gucy2c et vaccination Download PDF

Info

Publication number
EP4055176A4
EP4055176A4 EP20960974.2A EP20960974A EP4055176A4 EP 4055176 A4 EP4055176 A4 EP 4055176A4 EP 20960974 A EP20960974 A EP 20960974A EP 4055176 A4 EP4055176 A4 EP 4055176A4
Authority
EP
European Patent Office
Prior art keywords
gucy2c
vaccination
vaccines
gucy2c vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20960974.2A
Other languages
German (de)
English (en)
Other versions
EP4055176A1 (fr
Inventor
Adam E. Snook
Scott A Waldman
Trevor R. BAYBUTT
John C. FLICKINGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of EP4055176A1 publication Critical patent/EP4055176A1/fr
Publication of EP4055176A4 publication Critical patent/EP4055176A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01002—Guanylate cyclase (4.6.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP20960974.2A 2020-11-07 2020-11-09 Vaccins anti-gucy2c et vaccination Pending EP4055176A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062932499P 2020-11-07 2020-11-07
US202062933361P 2020-11-08 2020-11-08
PCT/US2020/059752 WO2022098372A1 (fr) 2020-11-07 2020-11-09 Vaccins anti-gucy2c et vaccination

Publications (2)

Publication Number Publication Date
EP4055176A1 EP4055176A1 (fr) 2022-09-14
EP4055176A4 true EP4055176A4 (fr) 2024-04-17

Family

ID=81458164

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20960974.2A Pending EP4055176A4 (fr) 2020-11-07 2020-11-09 Vaccins anti-gucy2c et vaccination

Country Status (3)

Country Link
EP (1) EP4055176A4 (fr)
AU (1) AU2020475819A1 (fr)
WO (1) WO2022098372A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY173390A (en) * 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of WO2022098372A1 *
SNOOK ADAM E. ET AL: "Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 7, no. 1, 23 April 2019 (2019-04-23), pages 1 - 12, XP055939172, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s40425-019-0576-2/fulltext.html> DOI: 10.1186/s40425-019-0576-2 *
SNOOK ADAM: "Metastatic Colorectal Cancer Immunotherapy with GUCY2C-Expressing Listeria monocytogenes", PROJECT REPORT, 1 September 2018 (2018-09-01), pages 45pp, XP055939177, Retrieved from the Internet <URL:https://apps.dtic.mil/sti/citations/AD1062516> [retrieved on 20220706] *

Also Published As

Publication number Publication date
WO2022098372A1 (fr) 2022-05-12
EP4055176A1 (fr) 2022-09-14
AU2020475819A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
EP4366768A4 (fr) Vaccins pan-coronavirus humains
EP4153730A4 (fr) Vaccins contre le sars-cov-2
IL272412A (en) Cytokine conjugates for the treatment of proliferative and infectious diseases
EP4125944A4 (fr) Antigènes de maladie infectieuse et vaccins
EP3463440A4 (fr) Compositions de vaccins à base de néo-épitopes et leurs méthodes d&#39;utilisation
MA47677A (fr) Vaccins peptidiques
EP2956544A4 (fr) Vaccins contre le cancer et méthodes de vaccination
EP4135847A4 (fr) Vaccin contre un coronavirus
EP4376883A4 (fr) Vaccins à arn
EP4034148A4 (fr) Vaccin sans antigène à base de biomatériau et son utilisation
DK4037708T3 (da) HBV-vacciner og fremgangsmåder til at behandle HBV
EP3419657A4 (fr) Vaccins anticancéreux à cellules entières et leurs procédés de sélection
IL309408A (en) Multivalent flu vaccines
MA53543A (fr) Vaccins peptidiques
EP2429577A4 (fr) Nouvelles souches de rotavirus humain et nouveaux vaccins
MA52011A (fr) Vaccins peptidiques contre l&#39;interleukine-31
EP4159234A4 (fr) Vaccin contre le sars-cov-2
IL286254A (en) Tlr4-tlr7 ligand formulations as vaccine adjuvants
EP4164687A4 (fr) Vaccin à coronavirus amélioré
MA52180A (fr) Vaccins thérapeutiques anti-abêta
EP4326320A4 (fr) Composition de vaccin avec adjuvant et procédés associés
IL304131A (en) HIV vaccines and methods of use
IL314393A (en) Human papillomavirus vaccines and uses of the same
EP4413144A4 (fr) Nanoparticules lipidiques de vaccin à arn
EP4448770A4 (fr) Vaccin efficace

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240318

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/09 20060101ALI20240312BHEP

Ipc: A61K 35/76 20150101ALI20240312BHEP

Ipc: C12N 5/10 20060101ALI20240312BHEP

Ipc: C12N 15/86 20060101ALI20240312BHEP

Ipc: C12N 7/00 20060101ALI20240312BHEP

Ipc: A61K 48/00 20060101ALI20240312BHEP

Ipc: C12N 15/861 20060101AFI20240312BHEP